The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Tofacitinib: A Review in Rheumatoid Arthritis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Novel treatment strategies in rheumatoid arthritis
Burmester, G. R., & Pope, J. E. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31491-5 · Cited by 1,068
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Fleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 461
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00006 · Cited by 448
Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
Hodge, J. A., Kawabata, T. T., Krishnaswami, S., Clark, J. D., Telliez, J., Dowty, M. E., Menon, S. S., Lamba, M., & Zwillich, S. H. (2016) · PubMed · Cited by 374
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., Kawabata, T., & Riese, R. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 353
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
Boyle, D. L., Soma, K., Hodge, J., Kavanaugh, A., Mandel, D., Mease, P., Shurmur, R., Singhal, A. K., Wei, N., Rosengren, S., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206028 · Cited by 300
Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285
Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34329 · Cited by 233
Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., Checchio, T., Tensfeldt, T. G., Hoffman, E., Riese, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0880-2 · Cited by 223
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
Souto, A., Maneiro, J. R., & Gómez-Reino, J. J. (2015) · Rheumatology · doi:10.1093/rheumatology/kev374 · Cited by 180
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Taylor, P. C., Weinblatt, M. E., Burmester, G. R., Rooney, T. P., Witt, S., Walls, C. D., Issa, M., Salinas, C. A., Saifan, C., Zhang, X., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40841 · Cited by 176
Yamanaka, H., Tanaka, Y., Takeuchi, T., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0932-2 · Cited by 154
LaBranche, T. P., Jesson, M. I., Radi, Z. A., Storer, C. E., Guzova, J. A., Bonar, S. L., Thompson, J., Happa, F. A., Stewart, Z. S., Zhan, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34649 · Cited by 147
McInnes, I. B., Kim, H., Lee, S., Mandel, D. R., Song, Y.-W., Connell, C. A., Luo, Z., Brosnan, M. J., Zuckerman, A. L., Zwillich, S. H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202442 · Cited by 127
Improving treatment adherence in patients with rheumatoid arthritis: what are the options?
Marengo, M. F., & Suarez-Almazor, M. E. (2015) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.15.39 · Cited by 118
Back to the future: oral targeted therapy for RA and other autoimmune diseases
O'Shea, J. J., Laurence, A., & McInnes, I. B. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.7 · Cited by 115
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Mócsai, A., Kovács, L., & Gergely, P. A. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-43 · Cited by 109
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019
Winthrop, K. L., Weinblatt, M. E., Bathon, J. M., Burmester, G. R., Mease, P. J., Crofford, L. J., Bykerk, V. P., Dougados, M., Rosenbaum, J. T., Xavier Mariette, A., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216151 · Cited by 107
Conaghan, P. G., Østergaard, M., Bowes, M. A., Wu, C., Fuerst, T. P., van der Heijde, D. M. F. M., Irazoque-Palazuelos, F. C., Soto‐Raices, O., Hrycaj, P., Xie, Z., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208267 · Cited by 104
Alten, R., Krüger, K., Rellecke, J., Schiffner-Rohe, J., Behmer, O., Schiffhorst, G., & Nolting, H.-D. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s117774 · Cited by 93
Strand, V., Kremer, J. M., Wallenstein, G. V., Kanik, K. S., Connell, C. A., Gruben, D. C., Zwillich, S. H., & Fleischmann, R. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0825-9 · Cited by 76
Strand, V., van Vollenhoven, R., Lee, E. B., Fleischmann, R., Zwillich, S. H., Gruben, D. C., Koncz, T., Wilkinson, B. E., & Wallenstein, G. V. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kev442 · Cited by 76
Charles‐Schoeman, C., Burmester, G. R., Nash, P. T., Zerbini, C. A. F., Soma, K., Kwok, K. K., Hendrikx, T. K., Bananis, E., & Fleischmann, R. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207178 · Cited by 75
Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis
Scott, L. J. (2013) · Drugs · doi:10.1007/s40265-013-0065-8 · Cited by 72
Curtis, J. R., Lanas, Á., John, A. K., Johnson, D. A., & Schulman, K. L. (2012) · Arthritis Care & Research · doi:10.1002/acr.21764 · Cited by 71
Strand, V., Burmester, G. R., Zerbini, C. A. F., Mebus, C. A., Zwillich, S. H., Gruben, D. C., & Wallenstein, G. V. (2014) · Arthritis Care & Research · doi:10.1002/acr.22453 · Cited by 65
Strand, V., Lee, E. B., Fleischmann, R., Alten, R., Koncz, T., Zwillich, S. H., Gruben, D. C., Wilkinson, B. E., Krishnaswami, S., & Wallenstein, G. V. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000308 · Cited by 64
Vieira, M.-C., Zwillich, S. H., Jansen, J. P., Smiechowski, B., Spurden, D., & Wallenstein, G. V. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.004 · Cited by 56
Isaacs, J. D., Zuckerman, A. L., Krishnaswami, S., Nduaka, C. I., Lan, S.-P., Hutmacher, M. M., Boy, M. G., Kowalski, K., Menon, S. S., & Riese, R. J. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4673 · Cited by 53
Bergrath, E., Gerber, R. A., Gruben, D. C., Lukić, T., Makin, C., & Wallenstein, G. V. (2017) · International Journal of Rheumatology · doi:10.1155/2017/8417249 · Cited by 42
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
Mariette, X., Chen, C., Biswas, P., Kwok, K. K., & Boy, M. G. (2017) · Arthritis Care & Research · doi:10.1002/acr.23421 · Cited by 40
Landewé, R., Connell, C. A., Bradley, J. D., Wilkinson, B. E., Gruben, D. C., Strengholt, S., & van der Heijde, D. M. F. M. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1106-y · Cited by 33
van Vollenhoven, R., Choy, E., Lee, E. B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.2134 · Cited by 8
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Amino acid metabolism in health and disease
Ling, Z.-N., Jiang, Y.-F., Ru, J.-N., Lu, J.-H., Ding, B., & Wu, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01569-3 · Cited by 545
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Metadata
- Authors
- Dhillon, S.
- Venue
- Drugs
- Published
- 2017-11-14
- Volume
- 77
- Issue
- 18
- Pages
- 1987-2001
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2770931697
- Cited by
- 302
- References
- 47
- FWCI
- 15.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.